NACDS: One Step Closer in Curbing Prescription Drug Abuse, Protecting Patients

Published Online: Tuesday, July 29, 2014

July 29, 2014, Arlington, Va. – A bipartisan bill that calls for a collaborative, coordinated approach to curbing prescription drug abuse and safeguarding patients is headed to the U.S. House for a vote later today.

The Ensuring Patient Access and Effective Drug Enforcement Act of 2013 (H.R. 4709) would establish a congressionally-mandated report from the Department of Health and Human Services (HHS), to explore opportunities to better coordinate federal and stakeholder activities in addressing prescription drug abuse and diversion without compromising access to medications for patients who legitimately need them.

Sponsored by Rep. Tom Marino (R-PA), Energy and Commerce Committee Vice Chair Rep. Marsha Blackburn (R-TN), Rep. Peter Welch (D-VT) and Rep. Judy Chu (D-CA), and cosponsored by ten representatives, the bill’s designated HHS report would be facilitated in consultation with the Drug Enforcement Agency and Office of the National Drug Control Policy, and with input from specific stakeholders, including pharmacy.

NACDS has emphasized its support of this legislation since its introduction, urging lawmakers to pass the bill in the interest of patients.

“We applaud Reps. Marino and Blackburn for their leadership on this bipartisan bill, and commend the House for bringing the bill to a vote, said NACDS President and CEO Steven C. Anderson, IOM, CAE. “NACDS and chain pharmacy are committed to partnering with federal and state agencies, law enforcement personnel, policymakers, and other stakeholders to work on viable strategies to simultaneously advance patient health and prevent prescription drug abuse. Today’s vote is a step closer to achieving these goals.”

“Looking ahead, we urge the U.S. Senate to move swiftly in passing legislation that will achieve this vital goal," said Anderson.

Latest Articles
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Carlos Aquino, founder and president of PharmaDiversion LLC, discusses timing of inspections from the Drug Enforcement Administration.
The FDA has again rejected AMAG Pharmaceuticals’ application for a single-dose version of hydroxyprogesterone caproate injection (Makena) to reduce the risk of preterm birth for at-risk women.
Latest Issues